证券之星消息，漱玉平民(301017)08月04日在投资者关系平台上答复投资者关心的问题。 投资者提问：董秘，你好。贵公司作为区域龙头，优先承接处方外流红利，包括：处方外流（门诊统 筹、带量采购）。请问：随着人口老龄化及健康消费升级，贵公司将如何把握医药零售市场，带来的发 展契机？谢谢！ 漱玉平民回复：您好，感谢您的关注。截至目前，处方外流相关政策在各地的执行细则与推进节奏存在 差异。从长期视角看，这一政策的深化落地，将对医药零售行业的销售业绩增长、客流量提升及多品类 协同发展产生深远影响。公司将持续密切跟踪国家及地方相关政策的动态与导向，在人口老龄化加速、 健康消费持续升级及医药行业政策深化变革的多重驱动下，积极主动布局，全力把握行业结构性机遇。 谢谢。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - The company is leveraging national policies and strategic partnerships to enhance its market position in the maternal and infant sector, particularly through the launch of the "Dashi Shuyu" store in Jinan, which integrates various health-related products and services [1] Group 1: Company Strategy - The company is responding positively to national policies, particularly the "child-rearing subsidy" policy, to capture growth opportunities in the maternal and infant market [1] - A strategic partnership with Taiwan's Dashi Pharmacy has been established to create the "Dashi Shuyu" store, marking a significant step in the company's health service layout [1] Group 2: Product Offering - The "Dashi Shuyu" store focuses on user needs and aims to build a comprehensive ecosystem that includes professional pharmaceuticals, maternal and infant products, health products, and selected cross-border goods [1] - The store is designed to provide consumers with a more comprehensive and convenient health living solution [1]

Core Viewpoint - The aggressive expansion strategy of the company has led to significant profit erosion, with a 79.23% year-on-year decline in net profit for 2024, marking a historical low since its listing [3][8]. Group 1: Financial Performance - The company reported a net profit of 114 million yuan for 2024, down 79.23% year-on-year, continuing a trend of declining profits for the second consecutive year [3][10]. - The company's revenue for 2024 was 18 billion yuan, reflecting a 3.57% increase compared to the previous year, but the net profit decline indicates a situation of "increased revenue without increased profit" [8][10]. - The company’s revenue sources include 71.88% from pharmaceutical retail, amounting to 12.94 billion yuan, and 22.71% from pharmaceutical wholesale, totaling 4.09 billion yuan [7]. Group 2: Expansion Strategy - The company has adopted a "land grab" strategy, opening over 1,000 new stores annually, with a total of 11,498 stores by the end of 2024, an increase of 1,243 stores from the beginning of the year [8][10]. - The company plans to continue expanding its presence in the Sichuan-Chongqing region while optimizing existing stores rather than significantly increasing the number of new stores [11]. Group 3: Investment in Healthcare Integration - The company has invested 24 million yuan in purchasing properties to enhance its healthcare integration business, which is seen as a strategic move for sustainable development [4][5]. - The healthcare integration business aims to create a network of services including medical care, rehabilitation, nursing, and health management, establishing a comprehensive ecosystem [6]. Group 4: Market Trends and Challenges - The aging population and policy incentives are driving the growth of the elderly care industry, which is projected to reach a market size of 30 trillion yuan by 2035 [5][6]. - Increased competition from online pharmaceutical platforms and tightening regulations have added pressure on traditional retail pharmacies, impacting profit margins [10].

Core Viewpoint - The National Healthcare Security Administration (NHSA) has launched a nationwide campaign to combat fraud and illegal activities in the pharmaceutical sector using drug traceability codes, resulting in multiple cases of illegal resale of reimbursed drugs being uncovered [1][14]. Group 1: Case Summaries - In Ulanqab City, Inner Mongolia, a community health service station was found to have sold drugs with duplicate traceability codes, leading to the recovery of 3,678 yuan in healthcare funds and a fine of 7,356 yuan [2]. - In Dezhou City, Shandong Province, a village health clinic was discovered to have sold drugs with traceability codes that had been reimbursed multiple times, resulting in a three-month suspension of its healthcare service agreement [3]. - A health clinic in Dazhu District, Chongqing, was found to have engaged in illegal drug exchanges, leading to a six-month suspension of its healthcare service agreement and penalties for the responsible personnel [4]. - A clinic in Suining City, Sichuan Province, was implicated in reselling drugs that had been previously reimbursed, resulting in penalties and recovery of healthcare funds [5]. - In Longli County, Guizhou Province, a health service was found to have resold drugs obtained through fraudulent means, leading to the recovery of 1,521.67 yuan in healthcare funds [7]. - A pharmacy in Nanyang City, Henan Province, was involved in the resale of drugs with duplicate traceability codes, resulting in the recovery of 67,200 yuan in healthcare funds and administrative penalties [8]. - In Wuzhong City, Ningxia, a pharmacy was found to have resold drugs that had been reimbursed, leading to a three-month suspension of its healthcare service agreement [9]. - Two insured individuals in Hangzhou, Zhejiang Province, were found to have illegally resold drugs, resulting in a loss of 439,854.73 yuan in healthcare funds [10]. - In Shuangyashan City, Heilongjiang Province, an individual was found to have resold drugs, leading to the recovery of 55,269.2 yuan in healthcare funds [11][12]. - An insured individual in Quanzhou City, Fujian Province, was found to have resold drugs, resulting in a loss of 5,139.45 yuan in healthcare funds [13]. Group 2: Impact of Drug Traceability Codes - The implementation of drug traceability codes has led to the collection of 53.098 billion drug traceability codes, significantly enhancing the monitoring and regulation of drug sales [13][14]. - The success of the traceability system is attributed to the collaborative efforts of regulatory bodies, pharmaceutical companies, and the active participation of the public in verifying drug authenticity [14].

Core Insights - The demand for mosquito repellent products has surged significantly due to seasonal factors and the impact of recent health concerns, particularly the spread of Chikungunya virus [1][2][4] Group 1: Sales Growth - Sales of mosquito repellent products, such as flower dew and repellent liquids, have seen remarkable increases, with flower dew sales up at least 45% year-on-year and repellent liquid sales doubling [2] - In the Guangdong region, online orders for mosquito repellent products have increased by over 150% in the past week [4] Group 2: Product Information - Flower dew is categorized into "regular" and "mosquito repellent" types, with the latter containing active ingredients like DEET and Picaridin, which provide varying durations of effectiveness [2] - The mosquito repellent flower dew containing DEET is suitable for outdoor use and can last between 2 to 8 hours [2] Group 3: Usage Guidelines - Users are advised to apply flower dew to exposed areas while avoiding sensitive regions and to keep it away from fire sources to prevent ignition [3] - Special precautions are recommended for children, such as avoiding application on hands to prevent ingestion and using it on clothing instead of directly on the skin [3] Group 4: Health Advisory - There is currently no specific antiviral treatment for Chikungunya; management focuses on rest, hydration, and symptomatic relief with over-the-counter medications [1][4] - Increased online consultations regarding Chikungunya prevention and treatment have been noted, indicating a heightened public awareness and concern [4]

证券之星 刘凤茹 证券之星注意到，白云山营收降幅较大的产品是阿莫西林系列，该产品2024年的营收同比下滑36.65%，对应营收为1.79亿元。内科用药方面，消渴丸2024年实现营收4.01亿元，同比下降23 大健康板块作为利润来源的第二大业务，主要为饮料、食品、保健品等产品的生产、研发与销售。大健康板块收入主要来自王老吉凉茶。对王老吉凉茶的销售，王老吉大健康公司及王老吉药业主 2024年，大健康板块实现营收97.05亿元，同比下降12.7%，该业务毛利率为43.12%，同比减少1.29个百分点。去年，王老吉大健康公司实现营收87.64亿元，同比下降12.47%；净利润11 证券之星注意到，白云山的大健康板块也一直在推出新品。白云山表示，刺柠吉、荔小吉作为公司的新品，尚在培育期。公司刺柠吉、荔小吉、核桃露、椰汁等产品将根据不同市场与渠道需求 股权投资"黑天鹅"，3.86亿减值吞利润 主业之外，白云山还提到，报告期内，根据《企业会计准则》的相关规定，公司对一心堂长期股权投资计提资产减值准备3.86 亿元。对一心堂的长期股权投资成为业绩"黑天鹅"。 回溯历史，2017年1月，白云山官宣拟以8亿元自有资金认购一心堂非 ...

Group 1 - The core viewpoint of the article is that Yifeng Pharmacy has decided to extend the completion date of its digitalization project from July 31, 2025, to December 31, 2025, due to the complexity and interconnectivity of the systems involved [5][6]. - The total investment for the digitalization project is 80.642 million yuan, with the company planning to use the same amount from the raised funds [3]. - As of June 30, 2025, the company has invested 73.621 million yuan in the digitalization project, achieving a progress rate of 91.29% [3]. Group 2 - The delay in the project is attributed to the challenges in integrating various systems such as product, logistics, finance, and human resources, which has led to a postponement in platform integration and promotion [4]. - The company has confirmed that the extension will not change the project implementation entity, method, total investment amount, or usage of the raised funds, ensuring that it aligns with the long-term development plan and interests of shareholders [5][6]. - The board of directors and the supervisory board have approved the extension, affirming that the decision complies with relevant laws and regulations [6].

Core Viewpoint - The company intends to use its own funds to pay for part of the investment project and subsequently replace it with raised funds, which is in compliance with regulatory requirements and aims to enhance the efficiency of fund utilization [1][5]. Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds, with net fundraising amounting to approximately 253.43 million yuan after deducting related expenses [1][2]. Investment Project Basic Situation - As of June 30, 2025, the total investment for the projects, including the Jiangsu Phase II, Hubei Pharmaceutical Sorting and Processing Center, and Hebei Pharmaceutical Warehouse, amounts to 253.43 million yuan, with 179.74 million yuan allocated from the raised funds [2]. Reasons for Using Own Funds - The company faces challenges in using raised funds directly for certain expenses, such as employee salaries and social insurance, which must be paid through the basic deposit account. Therefore, it plans to use up to 7.05 million yuan of its own funds for these payments and later replace them with raised funds [3][4]. Impact on the Company - The use of self-funds for project payments and subsequent replacement with raised funds is expected to improve fund utilization efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of the projects [4][5]. Review Procedures and Opinions - The company's board and supervisory committee have approved the proposal to use self-funds for the investment project, confirming that this action does not harm the interests of the company or its shareholders and complies with relevant regulations [5].

益丰药房（SH 603939，收盘价：24.22元）7月30日晚间发布公告称，公司第五届第十九次董事会会议 于2025年7月30日在湖南省长沙市金洲大道68号益丰医药物流园五楼会议室以现场加通讯方式召开。会 议审议了《关于取消监事会并修订的议案》等文件。 （文章来源：每日经济新闻） 2024年1至12月份，益丰药房的营业收入构成为：医药零售占比88.06%，医药批发占比8.76%，其他业 务占比3.19%。 ...

资金流向方面，今日主力资金净流出2521.48万元，占比成交额14.32%。其中，超大单净流出260.77万 元、占成交额1.48%，大单净流出2260.72万元、占成交额12.84%，中单净流出流出971.82万元、占成交 额5.52%，小单净流入3493.30万元、占成交额19.84%。 通过天眼查大数据分析，安徽华人健康医药股份有限公司共对外投资了18家企业，参与招投标项目33 次，知识产权方面有商标信息156条，专利信息21条，此外企业还拥有行政许可41个。 华人健康最新一期业绩显示，截至2025一季报，公司营业总收入12.67亿元、同比增长14.71%，归属净 利润6122.23万元，同比增长28.15%，扣非净利润5970.20万元，同比增长31.11%，流动比率1.189、速动 比率0.786、资产负债率57.07%。 来源：金融界 金融界消息 截至2025年7月29日收盘，华人健康（301408）报收于14.23元，下跌1.52%，换手率8.3%， 成交量12.38万手，成交金额1.76亿元。 天眼查商业履历信息显示，安徽华人健康医药股份有限公司，成立于2001年，位于合肥市，是一家以从 事零 ...